Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.43, beating the estimate of USD -0.5375.

EBIT: As of FY2026 Q2, the actual value is USD -8.217 M.

Financial Performance for Three Months Ended June 30, 2026

Research and Development (R&D) Expense

Elicio Therapeutics, Inc.’s R&D expense for the second quarter of 2026 was $6.8 million, a decrease of $0.2 million compared to $7.0 million for the second quarter of 2025. This decrease was primarily due to lower clinical trial costs as the Phase 2 study of ELI-002 7P transitioned from active dosing to the follow-up phase.

General and Administrative (G&A) Expense

G&A expense for the second quarter of 2026 was $3.6 million, an increase of $0.5 million from $3.1 million in the second quarter of 2025. This rise was mainly attributed to increased company headcount, leading to higher personnel costs, and a slight increase in professional fees.

Total Operating Expenses

Total operating expenses were $10.429 million for the second quarter of 2026, compared to $10.091 million for the same period in 2025.

Loss from Operations

Loss from operations for the second quarter of 2026 was - $10.429 million, compared to - $10.091 million for the second quarter of 2025.

Total Other Income (Expense), Net

Total other income, net, was $2.212 million for the second quarter of 2026, compared to - $0.470 million for the second quarter of 2025.

Net Loss

Net loss for the second quarter of 2026 was - $8.217 million, an improvement from - $10.561 million for the second quarter of 2025.

Comprehensive Loss

Comprehensive loss was - $8.221 million for the second quarter of 2026, compared to - $10.487 million for the second quarter of 2025.

Cash and Cash Equivalents

As of June 30, 2026, cash and cash equivalents totaled $23.480 million, compared to $18.563 million as of December 31, 2025.

Financing Activities

Elicio Therapeutics, Inc. raised net proceeds of $16.6 million in the second quarter of 2026, contributing to aggregate net proceeds of approximately $24.4 million year-to-date through its at-the-market program. In July 2026, the company raised aggregate gross proceeds of approximately $15.0 million in a registered direct offering.

Balance Sheet Highlights

As of June 30, 2026, total assets were $31.330 million, compared to $25.862 million as of December 31, 2025. Total liabilities were $23.393 million on June 30, 2026, down from $24.226 million on December 31, 2025. Total stockholders’ equity increased to $7.937 million as of June 30, 2026, from $1.636 million as of December 31, 2025.

Outlook / Guidance

Elicio Therapeutics, Inc. anticipates that its current cash and cash equivalents will support operations into the first quarter of 2027. The company plans to initiate a Phase 1 combination study of ELI-002 7P in metastatic pancreatic cancer in the fourth quarter of 2026. This study will evaluate ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor.